ReviewChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Case-based review: Craniopharyngioma treated with intracystic peginterferon.
Review in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCraniopharyngiomas are benign tumors with a challenging management due to the excessive morbidity of the classical therapeutic approaches. This has led to the current trend of a multimodal approach with more conservative surgical options. CASE REPORT: We present the case of a 6-year old patient diagnosed with a giant multicystic and rapidly recurrent craniopharyngioma, showing the current trends towards a multimodal therapeutic approach with less aggressive surgical options. We emphasize the use of two different intracystic cycles of a new formulation of pegylated 2a interferon. We make a review of the available literature focusing on historical and current treatment options.
conclusionCraniopharyngiomas remain a challenge due to the morbidity caused by both the disease and its treatment. The current trend towards a more conservative approach has many alternative treatment options, with intracystic pegyladed 2a interferon being a safe and effective choice, even in consecutive administrations.
Indexed as
Identifiers
41348206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.